Ligand Pharma (LGNT) PT Raised to $160 at H.C. Wainwright

October 5, 2016 7:49 AM EDT
Get Alerts LGND Hot Sheet
Price: $103.18 +1.90%

Rating Summary:
    8 Buy, 3 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade LGND Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

H.C. Wainwright analyst Carol Ann Werther reiterated a Buy rating and lifted her prcice target on Ligand Pharma (NASDAQ: LGND) to $160.00 (from $146.00), citing three recent positive events.

Werther highlighted:

  • Partner Retrophin announced the Sparsentan’s Phase 2 DUET study met the primary efficacy endpoint for the overall treatment group in focal segmental glomerulosclerosis (FGFS).
  • LGND began a Phase 2 clinical trial with LGD-6972, a glucagon receptor antagonist (GRA), for the treatment of type 2 diabetes (T2D).
  • LGND licensed several therapeutic programs to a start up company Seelos.

For an analyst ratings summary and ratings history on Ligand Pharma click here. For more ratings news on Ligand Pharma click here.

Shares of Ligand Pharma closed at $100.57 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change

Related Entities

H.C. Wainwright

Add Your Comment